{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Per Response - Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions;","groups":[{"description":"Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nlapatinib ditosylate: Given orally\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Lapatinib Ditosylate)"}],"paramType":"NUMBER","populationDescription":"36 assessable participants.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Objective Response Rates (Partial and Complete Responses)","type":"PRIMARY","unitOfMeasure":"participants"}